BNF:

8.2.4

Status:

Do Not Prescribe (DNP), Red

Decision Date:

February 2017

Comments

RED:^1,2,3 NICE TA427: Pomalidomide for multiple myeloma previously treated with lenalidomide and bortezomib.

DO NOT PRESCRIBE (DNP)⁶: NICE TA602: Pomalidomide with bortezomib and dexamethasone for treating relapsed or refractory multiple myeloma. (Terminated appraisal, decision date - Oct 2019)

Do Not Prescribe (DNP) Drug Classifications

• 6: Have NICE guidance that recommends they should not be used

Red Drug Classifications

• 1: Requiring specialist assessment to enable patient selection, initiation and ongoing treating
• 2: Requiring long term on-going monitoring of efficacy by a specialist and not suitable for shared care
• 3: Requiring long term on-going monitoring of toxicity by a specialist (either because of difficulty in recognising side effects or high cost of investigations to identify toxicity)

search again